Literature DB >> 16797705

Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients.

R Bussolari1, O Candini, D Colomer, F Corradini, C Guerzoni, S A Mariani, S Cattelani, C Silvestri, L Pecorari, I Iacobucci, S Soverini, T Fasano, G Martinelli, F Cervantes, B Calabretta.   

Abstract

The c-myb gene encodes a transcription factor required for proliferation, differentiation and survival of normal and leukemic hematopoietic cells. c-Myb has a longer half-life in BCR/ABL-expressing than in normal cells, a feature which depends, in part, on PI-3K/Akt-dependent regulation of proteins interacting with the leucine zipper/negative regulatory region of c-Myb. Thus, we asked whether the stability of c-Myb in leukemic cells might be enhanced by mutations interfering with its degradation. We analyzed the c-myb gene in 133 chronic myeloid leukemia (CML) patients in chronic phase and/or blast crisis by denaturing-high performance liquid chromatography (D-HPLC) and sequence analysis of PCR products corresponding to the entire coding sequence and each exon-intron boundary. No mutations were found. We found four single nucleotide polymorphisms (SNPs) and identified an alternatively spliced transcript lacking exon 5, but SNPs frequency and expression of the alternatively spliced transcript were identical in normal and CML cells. Thus, the enhanced stability of c-Myb in CML blast crisis cells and perhaps in other types of leukemia is not caused by a genetic mechanism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16797705     DOI: 10.1016/j.leukres.2006.05.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.

Authors:  Maria Rosa Lidonnici; Francesca Corradini; Todd Waldron; Timothy P Bender; Bruno Calabretta
Journal:  Blood       Date:  2008-01-28       Impact factor: 22.113

2.  Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells.

Authors:  Harish Kumar; Sourav Chattopadhyay; Nabanita Das; Sonal Shree; Dinesh Patel; Jogeswar Mohapatra; Anagha Gurjar; Sapana Kushwaha; Abhishek Kumar Singh; Shikha Dubey; Kiran Lata; Rajesh Kushwaha; Riyazuddin Mohammed; Krishnarup Ghosh Dastidar; Namrata Yadav; Achchhe Lal Vishwakarma; Jiaur Rahaman Gayen; Sanghamitra Bandyopadhyay; Abhijit Chatterjee; Mukul Rameshchandra Jain; Anil Kumar Tripathi; Arun Kumar Trivedi; Naibedya Chattopadhyay; Ravishankar Ramachandran; Sabyasachi Sanyal
Journal:  Haematologica       Date:  2019-08-01       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.